Recently Issued Guidance Documents

Should you find a Web link (URL) embedded within guidance documents that does not work or other documents posted on the FDA Web site, please try searching for the document using the document title. If you need further assistance, please go to Contact FDA.

---

• Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products; Draft Guidance for Industry
  CBER/CDER, September 2019

• Safety and Performance Based Pathway; Draft Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER,  September 2019

• Safer Technologies Program for Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER,  September 2019

• Refuse to Accept Policy for 510(k)s; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• The Abbreviated 510(k) Program; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• The Special 510(k) Program; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• Format for Traditional and Abbreviated 510(k)s; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• User Fees and Refunds for De Novo Classification Requests; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• Acceptance Review for De Novo Classification Requests; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• Humanitarian Device Exemption (HDE) Program; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER, September 2019

• Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products; Guidance for Industry
  CDER/CBER, August 2019

• Male Breast Cancer: Developing Drugs for Treatment; Draft Guidance for Industry
  CDRH/CBER, August 2019

• Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications; Guidance for Industry and Food and Drug Administration Staff
  CDRH/CBER,  August 2019

• Child-Resistant Packaging Statements in Drug Product Labeling; Guidance for Industry
  CDER/CBER, August 2019

• Fabry Disease: Developing Drugs for Treatment; Draft Guidance for Industry
  CDER/CBER, August 2019

• Bacterial Vaginosis:  Developing Drugs for Treatment; Guidance for Industry
  CDER/CBER, August 2019

• Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers; Draft Guidance for Industry
  CDER/CBER/CDRH/CVM/CFSAN/CTP, July 2019

• Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention; Guidance for Industry
  CDER/CBER, July 2019

• Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications; Draft Guidance for Industry
  CDER/CBER, July 2019

• Risk Evaluation and Mitigation Strategies: Modifications and Revisions; Guidance for Industry
  CDER/CBER, July 2019

• Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products – Content and Format; Draft Guidance for Industry
  CDER/CBER, July 2019

• Instructions for Use – Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products – Content and Format; Draft Guidance for Industry
  OCP/CDER/CBER,  July 2019